Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

AVI-7288 for Marburg Virus in Nonhuman Primates and Humans.

Heald AE, Charleston JS, Iversen PL, Warren TK, Saoud JB, Al-Ibrahim M, Wells J, Warfield KL, Swenson DL, Welch LS, Sazani P, Wong M, Berry D, Kaye EM, Bavari S.

N Engl J Med. 2015 Jul 23;373(4):339-48. doi: 10.1056/NEJMoa1410345.

2.

A single phosphorodiamidate morpholino oligomer targeting VP24 protects rhesus monkeys against lethal Ebola virus infection.

Warren TK, Whitehouse CA, Wells J, Welch L, Heald AE, Charleston JS, Sazani P, Reid SP, Iversen PL, Bavari S.

MBio. 2015 Feb 10;6(1). pii: e02344-14. doi: 10.1128/mBio.02344-14.

3.

Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against ebola virus and marburg virus: results of two single-ascending-dose studies.

Heald AE, Iversen PL, Saoud JB, Sazani P, Charleston JS, Axtelle T, Wong M, Smith WB, Vutikullird A, Kaye E.

Antimicrob Agents Chemother. 2014 Nov;58(11):6639-47. doi: 10.1128/AAC.03442-14. Epub 2014 Aug 25.

4.

Stroke in a patient with human immunodeficiency virus and syphilis treated with penicillin and antiretroviral therapy.

Bucher JB, Golden MR, Heald AE, Marra CM.

Sex Transm Dis. 2011 May;38(5):442-4. doi: 10.1097/OLQ.0b013e3181ffa5d0.

PMID:
21124258
5.

A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus.

Vardas E, Kaleebu P, Bekker LG, Hoosen A, Chomba E, Johnson PR, Anklesaria P, Birungi J, Barin B, Boaz M, Cox J, Lehrman J, Stevens G, Gilmour J, Tarragona T, Hayes P, Lowenbein S, Kizito E, Fast P, Heald AE, Schmidt C.

AIDS Res Hum Retroviruses. 2010 Aug;26(8):933-42. doi: 10.1089/aid.2009.0242.

PMID:
20666584
6.

Single-joint outcome measures: preliminary validation of patient-reported outcomes and physical examination.

Heald AE, Fudman EJ, Anklesaria P, Mease PJ; 13G01 Study Team.

J Rheumatol. 2010 May;37(5):1042-8. doi: 10.3899/jrheum.090827. Epub 2010 Mar 15.

PMID:
20231202
7.

Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 Study.

Mease PJ, Wei N, Fudman EJ, Kivitz AJ, Schechtman J, Trapp RG, Hobbs KF, Greenwald M, Hou A, Bookbinder SA, Graham GE, Wiesenhutter CW, Willis L, Ruderman EM, Forstot JZ, Maricic MJ, Dao KH, Pritchard CH, Fiske DN, Burch FX, Prupas HM, Anklesaria P, Heald AE.

J Rheumatol. 2010 Apr;37(4):692-703. doi: 10.3899/jrheum.090817. Epub 2009 Dec 23.

PMID:
20032102
8.

Assessing single joints in arthritis clinical trials.

Keen HI, Bingham CO 3rd, Bradley LA, Conaghan PG, Heald AE, Kaeley GS, Maksymowych WP, Moskowitz RW, Schumacher HR Jr, Woodworth TE, Mease PJ.

J Rheumatol. 2009 Sep;36(9):2092-6. doi: 10.3899/jrheum.090364. Review.

PMID:
19738219
9.

Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study.

Mease PJ, Hobbs K, Chalmers A, El-Gabalawy H, Bookman A, Keystone E, Furst DE, Anklesaria P, Heald AE.

Ann Rheum Dis. 2009 Aug;68(8):1247-54. doi: 10.1136/ard.2008.089375. Epub 2008 Aug 4.

PMID:
18678578
10.

A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine.

Mehendale S, van Lunzen J, Clumeck N, Rockstroh J, Vets E, Johnson PR, Anklesaria P, Barin B, Boaz M, Kochhar S, Lehrman J, Schmidt C, Peeters M, Schwarze-Zander C, Kabamba K, Glaunsinger T, Sahay S, Thakar M, Paranjape R, Gilmour J, Excler JL, Fast P, Heald AE.

AIDS Res Hum Retroviruses. 2008 Jun;24(6):873-80. doi: 10.1089/aid.2007.0292.

PMID:
18544020
11.

Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial.

Moss RB, Milla C, Colombo J, Accurso F, Zeitlin PL, Clancy JP, Spencer LT, Pilewski J, Waltz DA, Dorkin HL, Ferkol T, Pian M, Ramsey B, Carter BJ, Martin DB, Heald AE.

Hum Gene Ther. 2007 Aug;18(8):726-32.

PMID:
17685853
12.

Evaluation of exposure and health care worker response to nebulized administration of tgAAVCF to patients with cystic fibrosis.

Croteau GA, Martin DB, Camp J, Yost M, Conrad C, Zeitlin PL, Heald AE.

Ann Occup Hyg. 2004 Nov;48(8):673-81. Epub 2004 Oct 26.

PMID:
15507460
13.

Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial.

Moss RB, Rodman D, Spencer LT, Aitken ML, Zeitlin PL, Waltz D, Milla C, Brody AS, Clancy JP, Ramsey B, Hamblett N, Heald AE.

Chest. 2004 Feb;125(2):509-21.

PMID:
14769732
14.

Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study.

Flotte TR, Zeitlin PL, Reynolds TC, Heald AE, Pedersen P, Beck S, Conrad CK, Brass-Ernst L, Humphries M, Sullivan K, Wetzel R, Taylor G, Carter BJ, Guggino WB.

Hum Gene Ther. 2003 Jul 20;14(11):1079-88.

PMID:
12885347
15.

A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma.

Villaret D, Glisson B, Kenady D, Hanna E, Carey M, Gleich L, Yoo GH, Futran N, Hung MC, Anklesaria P, Heald AE.

Head Neck. 2002 Jul;24(7):661-9.

PMID:
12112540
16.

Protease inhibitors are associated with a slowed progression of HIV-related renal diseases.

Szczech LA, Edwards LJ, Sanders LL, van der Horst C, Bartlett JA, Heald AE, Svetkey LP.

Clin Nephrol. 2002 May;57(5):336-41.

PMID:
12036191
17.

HIV infection: treatment outcomes in older and younger adults.

Wellons MF, Sanders L, Edwards LJ, Bartlett JA, Heald AE, Schmader KE.

J Am Geriatr Soc. 2002 Apr;50(4):603-7.

PMID:
11982658
18.

Skin test reactivity and cellular immune responses to Mycobacterium avium sensitin in AIDS patients at risk for disseminated M. avium infection.

von Reyn CF, Williams PL, Lederman HM, McCutchan JA, Koletar SL, Murphy RL, Cohn SE, Evans T, Heald AE, Colquhoun D, Bassily EL, Currier JS.

Clin Diagn Lab Immunol. 2001 Nov;8(6):1277-8.

19.

A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 x 106 /l.

Koletar SL, Heald AE, Finkelstein D, Hafner R, Currier JS, McCutchan JA, Vallee M, Torriani FJ, Powderly WG, Fass RJ, Murphy RL; ACTG 888 Study Team.

AIDS. 2001 Aug 17;15(12):1509-15.

PMID:
11504983
20.
21.

Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team.

Currier JS, Williams PL, Koletar SL, Cohn SE, Murphy RL, Heald AE, Hafner R, Bassily EL, Lederman HM, Knirsch C, Benson CA, Valdez H, Aberg JA, McCutchan JA.

Ann Intern Med. 2000 Oct 3;133(7):493-503.

PMID:
11015162
22.

Effect of antimicrobial and anti-inflammatory medications on the sense of taste.

Schiffman SS, Zervakis J, Westall HL, Graham BG, Metz A, Bennett JL, Heald AE.

Physiol Behav. 2000 Jun 1-15;69(4-5):413-24.

PMID:
10913779
23.

Effect of the nucleoside analogs zidovudine, didanosine, stavudine, and lamivudine on the sense of taste.

Schiffman SS, Zervakis J, Shaio E, Heald AE.

Nutrition. 1999 Nov-Dec;15(11-12):854-9.

PMID:
10575660
24.

Effect of protease inhibitors on the sense of taste.

Schiffman SS, Zervakis J, Heffron S, Heald AE.

Nutrition. 1999 Oct;15(10):767-72.

PMID:
10501290
25.

Association of plasma levels of human immunodeficiency virus type 1 RNA and oropharyngeal Candida colonization.

Gottfredsson M, Cox GM, Indridason OS, de Almeida GM, Heald AE, Perfect JR.

J Infect Dis. 1999 Aug;180(2):534-7.

PMID:
10395877
26.

Taste and smell complaints in HIV-infected patients.

Heald AE, Pieper CF, Schiffman SS.

AIDS. 1998 Sep 10;12(13):1667-74.

PMID:
9764787
27.

Clinical complications of HIV infection.

Heald AE, Hicks CB.

Radiol Clin North Am. 1997 Sep;35(5):1007-27. Review.

PMID:
9298087
28.

Brain biopsy for HIV-infected patients with intracranial lesions.

Heald AE.

N C Med J. 1997 Mar-Apr;58(2):106-9. No abstract available.

PMID:
9088136
29.

Taste and smell. Neglected senses that contribute to the malnutrition of AIDS.

Heald AE, Schiffman SS.

N C Med J. 1997 Mar-Apr;58(2):100-4.

PMID:
9088135
30.

Differentiation of central nervous system lesions in AIDS patients using positron emission tomography (PET).

Heald AE, Hoffman JM, Bartlett JA, Waskin HA.

Int J STD AIDS. 1996 Aug-Sep;7(5):337-46.

PMID:
8894823
31.

Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction.

Heald AE, Hsyu PH, Yuen GJ, Robinson P, Mydlow P, Bartlett JA.

Antimicrob Agents Chemother. 1996 Jun;40(6):1514-9.

32.
33.

Taste and smell losses in HIV infected patients.

Graham CS, Graham BG, Bartlett JA, Heald AE, Schiffman SS.

Physiol Behav. 1995 Aug;58(2):287-93.

PMID:
7568432
34.

Cryptosporidium spread in a group residential home.

Heald AE, Bartlett JA.

Ann Intern Med. 1994 Sep 15;121(6):467-8. No abstract available.

PMID:
8053626
35.

Needlestick injuries among resident physicians.

Heald AE, Ransohoff DF.

J Gen Intern Med. 1990 Sep-Oct;5(5):389-93.

PMID:
2231033

Supplemental Content

Loading ...
Support Center